One hundred forty-seven consecutive coronary bypass patients were enrolled in a randomized, double-blind, risk-stratified, placebo-controlled prospective trial evaluating the effect on graft patency of 325 mg tid aspirin (ASA) plus 75 mg tid dipyridamole (DP) or ASA alone. One hundred twenty-seven patients (399 total grafts) underwent surgery, initiation of drug therapy 67 + 27 (SD) hr postoperatively, five clinic visits, and repeat angiography at 1 year. A logistic regression statistical model was used to determine the effects of 28 different measured variables on graft patency and to adjust for these effects in determining the relationship between antiplatelet therapy and graft occlusion. No patient-specific variable contributed significantly to the prediction of occlusion in either the placebo or the treated group. Six graft-specific variables (arterial diameter, severity of stenosis, graft flow, reactive hyperemia, presence or absence of collaterals, and graft type) did contribute and were included in the model. Twenty-one percent of placebo-treated grafts became occluded. Compared with placebo, the relative risk of graft occlusion with ASA was 0.47 (p = .04); with ASA + DP, it was 0.50 (p = .04). This benefit was principally due to reduction of occlusion in the most common and presumably most important groups of grafts, those in which flow exceeded 40 ml/min, or supplying arteries having luminal diameters greater than 1.5 mm. Grafts lacking reactive hyperemia had a 32% occlusion frequency in placebo-treated patients; relative risk of their occlusion averaged 0.26 (p < .01) with platelet-inhibiting therapy. Therapy is most effective if started on or before the second postoperative day. ASA and the combination of ASA and DP given after surgery were equally effective in maintaining graft patency. Thus, early postoperative ASA appears to be a simple, inexpensive, and effective form of therapy for most bypass patients. We question the need for the addition of preoperative or postoperative DP to this ASA regimen. Circulation 72, No. 1, 138-146, 1985. EACH YEAR in the United States, over 100,000 patients undergo coronary bypass surgery,' and approximately 300,000 saphenous vein grafts are implanted. Since the clinical success of this operation is found to depend on the completeness of revascularization,24 measures to improve the patency of bypass grafts are of potential value.
2 weeks,5-8 as are about 17% and 20% after 6 and 12 months, respectively.5-9 The occlusion rate is 2% to 4% per year in those still patent at 1 year. 1012 The early graft patency rate is reported to depend also on the experience of the surgeon,5 the sex of the patient,'3 the artery grafted, 14 the operative graft flow, 5 the severity of the proximal arterial stenosis, '6, 1 ' the size of the grafted artery, 16 18 and the presence of reactive hyperemia. 16 The great majority of occlusive episodes in the first 2 months are thrombotic, after which thrombosis usually combines with accelerated intimal fibromuscular hyperplasia to obstruct the graft.'9 20 Beyond 1 year, grafts usually occlude with progressive atherosclerosis. 19 20 Thrombus formation in the arterial circulation is retarded by drugs that inhibit platelet function.2' Intimal fibromuscular hyperplasia is accelerated by a mitogenic substance released from the a-granules of the platelet,22 23 and is retarded, experimentally, by platelet-inhibiting therapy. 24 Because of the implied role of the platelet in these two mechanisms of graft occlusion, therapy designed to limit adhesion and aggregation of platelets and their release of a-granules would hypothetically improve graft patency. We investigated this hypothesis in a randomized, double-blind, riskstratified comparison of aspirin (ASA), aspirin plus dipyridamole (ASA + DP), and placebo in a sufficiently large group of consecutive patients to confirm a 50% drug benefit, if present, at p < .05 with a power of 0.90. We have found that there is a substantial benefit with respect to graft patency from early postoperative platelet-inhibiting therapy, particularly for the most important and common groups of grafts those with moderate or high graft flow perfusing moderate or large arteries.
Methods
Patients. One hundred forty-seven consecutive eligible male coronary bypass patients, ages 34 to 70 years, were enrolled in a prospective study of platelet-inhibiting therapy during the year after surgery. Forty-four of 191 patients (23%) undergoing elective coronary bypass surgery during the 3 year enrollment period were excluded from the study because of ASA intolerance (n = 4), ASA requirement (n = 3), history of peptic ulcer disease (n = 9), prohibitive travel distance (n = 5), refusal (n = 19), or insufficient time for preoperative interview (n = 4). One hundred twenty-seven completed the protocol, which included surgery, clinical monitoring for 1 year, and readmission for postoperative evaluation. Patients were enrolled between catheterization and the operation after fully informed written consent was obtained. Preoperative data collected included that obtained by history, physical examination, laboratory screening, electrocardiography, and exercise testing (Bruce protocol) and pertinent information from the catheterization.
Surgery. After pentothal and nitrous oxide induction and ethrane inhalation anesthesia and midsternal thoracotomy, cardiopulmonary bypass was initiated in each patient with 2.4 liters of balanced electrolyte and albumin pump prime and a bubble oxygenator. Over the course of the 31/2 year enrollment period (1976 to 1980), three techniques for myocardial preservation were used: (1) normothermic intermittent cross-clamping, (2) hypothermic intermittent cross-clamping with cold arrest, and (3) cold potassium cardioplegia.25 Three hundred ninety-nine saphenous vein grafts were placed to previously unoperated arteries with 50% or more stenosis; of these, 39 veins (80 grafts) were the continuity type anastomosed side-to-side to one or more diseased arteries and end-to-side to another.
Veins were resected with gentle handling and, if small, were distended with blood at moderate pressure. Sites of possible injury by traumatic clamps were resected; only broad "nontraumatic" bulldog clamps were used during graft placement. When the distal anastomosis was nearly complete, a series of olive-tip probes calibrated in 0.5 mm diameter increments was passed proximally and distally into the grafted artery to estimate vessel caliber and to ensure the patency of the anastomosis. Just before chest closure, flow was measured electromagnetically* in each leg of the grafts. Reactive hyperemia was determined as the percent increase above baseline flow after temporary graft occlusion for 15 sec. Study protocol. Therapy was assigned before surgery to patients in a fully randomized, double-blind fashion. Protocol treatment groups were as follows: (1) ASA + DP: 325 mg ASA plus 75 mg DP to be taken three times daily, 1 hr before meals, (2) ASA: 325 mg ASA plus a DP placebo taken three times a day before meals, and (3) placebo: double placebo taken three times a day as above.
The randomized drug assignment was stratified for preoperative cigarette smoking and fasting serum cholesterol levels to balance the distribution of these two presumed risk factors in each group. For the first 78 patients, protocol drug was scheduled to start on the third postoperative day unless bleeding or thrombocytopenia occurred. Because no complications occurred, the next 49 consecutive patients were started on therapy on the second postoperative day. On the average, therapy was initiated 67 27(SD) hr after the patient left the operating room. The first dose was given by the principal investigator. Subsequent doses were given by the nursing staff in compliance with written orders. In-hospital drug compliance was checked daily by the project administrative assistant using patient interviews and review of the charted medications. Drug instructions were reviewed with the patient at the time of hospital discharge.
After discharge, patients were seen in the clinic as needed, routinely at week 1 and 4 and then at 3, 6, and 9 months after surgery. Follow-up was conducted by the principal investigator. Patients were instructed to avoid platelet-active medications and were given acetaminophen for analgesia. Hypertension was treated with thiazide diuretics and a-methyldopa. Patients' drug supplies were renewed at each 3 month clinic visit. Compliance was assessed by count of the returned pills and by urine salicylate and Ivy bleeding time measured and recorded by independent technicians at the 6 month visit and the 12 month readmission. At 1 year, evaluation included history, physical examination, laboratory screening, treadmill testing, and catheterization.
Catheterization data. Aortic and left ventricular pressures were measured, the latter at high gain with zero level at a measured midchest position. Ejection fraction was computed from the 30 degree right anterior oblique angiogram.26 The native coronary arteriograms were performed in a defined sequence of projections, which was the same in both studies. A detailed map of the coronary anatomy documented the distribution and size of all important branches, the location and severity of focal narrowing, the collateral anatomy, and the direction of flow. At the 1 year recatheterization, native vessel arteriograms were repeated. All grafts were selectively catheterized, guided by surgically implanted metal markers, and were opacified and filmed in three or four of the original projection angles. Grafts (distal anastomoses) fully visualized to supply the distal artery during selective injection were called "patent"; otherwise they were considered "occluded." The details of the original vascular map were confirmed by review of both sets of films, which were projected simultaneously at fivefold magnification on two parallel overhead projectors. The anatomy and patency of each graft and changes in native vessel disease were then added to the vascular map in color code. Arterial diameter at each point of anastomosis was estimated from the preoperative arteriogram by caliper comparison with the catheter. Data analysis. Patient-specific and graft-specific variables were prospectively defined and measured to determine the utility of each as a predictor of graft occlusion and to allow adjustments for them, if necessary, in evaluating the effect of the platelet-inhibiting therapy. Preoperative, intraoperative, and postoperative measurements were included.
The analysis of the effect of the antiplatelet therapy was performed by logistic regression27 in which the dependent variable was the occlusion or nonocclusion (y = 1 or 0) of a graft at 1 year. Independent variables included graft-specific and patient-specific measurements, as well as a dichotomous variable that indicated whether the therapy administered was ASA alone (1 = yes, 0 = no) or ASA + DP. When both therapy variables were equal to zero, the therapy was placebo. Thus, these two dichotomous variables specified the therapy group for each graft.
Logistic regression is a nonlinear analog of multiple linear regression, and can be used to relate the probability of the occurrence of a dichotomous outcome (occlusion, nonocclusion) to several independent variables, which can be categorical or continuous. 25 . 29 The logistic model is of the form 
Using maximum likelihood techniques, one can estimate Jail the coefficient of independent variable Xj in the model, which measures the effect of X, on the probability of occlusion. The test of lj = 0 is the test of whether variable Xj (for example, the administration of ASA + DP) has a significant effect on the probability of occlusion. The use of logistic regression was necessary because the experimental unit of interest is the occlusion or nonocclusion of an individual graft, yet it is not possible to randomize individual grafts to therapy. This presents a dilemma in the analysis of the data. An analysis that used the patient as the observational unit of interest (e.g., comparing the proportions of patients who had all grafts patent) was deemed inappropriate because it ignored the fact that certain graft-specific variables such as graft flow and arterial diameter were important determinants of occlusion and it also reduced the effective sample size considerably. A precise evaluation of the effect of therapy on graft occlusion should include adjustments for imbalances among the treatment groups of variables predictive of occlusion. Since the variables predictive of occlusion were graft specific, and since individual grafts were not randomized, the randomization procedure itself could not be expected to achieve balance among the groups with respect to graft-specific variables. The logistic model used the graft as the observational unit and allowed adjustment for graftspecific variables, although the analysis became "observational" in nature since the grafts were not randomized. Use of this model avoided the assumption of independent behavior of two grafts in the same patient by assuming that any dependence of two such grafts could be modeled by including appropriate patient-specific and graft-specific variables.
As a first step, univariate logistic regression analyses were performed with use of each of the 28 variables as a single independent variable to determine which were significantly related to occlusion and should, therefore, be included as covariates in evaluating the effect of therapy. Analyses were performed separately in the placebo and the drug-treated groups to avoid the designation of a variable as related to occlusion merely because it correlated with drug administration. No patientspecific and six graft-specific variables were identified as significantly related to occlusion in either the placebo or platelet-inhibition group or both. The six graft-specific varia-bles were included as covariates in the subsequent analysis that evaluated the effects of therapy.
Measurements were obtained for all grafts for four of the six independent covariates. Flow and reactive hyperemia were measured in virtually every individual graft. However, these data could not always be obtained for each anastomosis of continuity-type grafts. As a consequence, direct measurements were missing for 53 of the 2394 covariate values essential to the logistic regression analysis. However, graft flow was significantly predicted by proximal stenosis and vessel size, and reactive hyperemia was predicted by proximal stenosis and receipt of collaterals. By use of these predictive relationships, missing flow and hyperemia values were estimated for inclusion in the logistic analysis.
The tests for the significance of the effects of ASA or ASA + DP were performed by fitting a logistic model with the six covariates plus the dichotomous therapy group variables. The estimated coefficient of a variable in this model divided by its standard error follows a standard normal distribution, and allows one to test whether the variable contributes a significant amount of information toward predicting graft occlusion while adjusting for the effect of other variables in the model. For grafts in the ASA or ASA + DP groups, the risk of occlusion relative to that in the placebo group, with all other covariates held constant, is estimated by the odds ratio, the exponential of the coefficient of the therapy variable (e:). A significant odds ratio is one that differs significantly from 1.0.
In further testing the results (e.g., in looking at the numbers of occluded grafts as a determinant of postoperative ischemia), some simple comparisons of proportions and means were made.
In these, the x2 test for contingency tables was used for categorical data, and one-way analysis of variance was used to compare means for continuous data. All p values computed were based on two-sided tests.
Results
Enrollment and dropout. One hundred forty-seven patients were enrolled and began protocol therapy in the early postoperative period. One hundred twenty-seven patients completed the protocol, including the catheterization procedure at 1 year. Table 1 summarizes the reasons for failure to complete the protocol. There were no significant differences among therapeutic groups with respect to number enrolled or dropouts. Compliance: pill count. Medications were taken regularly, under supervision, by all patients during their initial 7 to 12 day hospital stay, starting 67 + 27(SD) hr after surgery. Unused protocol drugs were returned at the 3 month clinic visits and were counted. Sixtyone percent of patients had average pill-count compliance of greater than 90%. A scoring system awarded two points to those taking at least 75% of the specified doses during the first 3 month period and one point for 75% or greater compliance during each of the three succeeding 3 month periods. Maximum score was thus five points. A compliance score of five was attained by 72% of patients, that of at least four by 88%, and that of at least three by 94%. Unannounced urine samples were obtained at 6 and 12 months and tested with Trindler's solution for salicylate. These tests were positive 73% of the time in patients on ASA + DP and 72% of the time in patients on ASA. Results of both tests were negative in only three patients in each group. Positive test results indicative of casual ASA use were obtained 4% of the time in patients on placebo. Ivy bleeding time was measured at 6 and 12 months. It averaged 2.7 ± 1.6 min in placebo patients, and was significantly increased at 5.1 + 2.6 min (p < .001) in thJ ASA + DP group and at 4.9 ± 2.7 min (p < .001) in the ASA group.
Factors predictive of graft occlusion. Twenty-eight variables, continuous and dichotomous, were screened in preliminary logistic regression analysis for their predictive value. Dichotomous variables (e.g., presence or absence of collaterals) were entered as 1 or 0. For purposes of this screening, a variable was called predictive if the logistic regression indicated that it was significantly (p < .05) associated with occlusion in either the placebo or the drug-treated groups.
None of the preoperative clinical variables tested were significantly related to graft occlusion, including age, cigarette smoking, cholesterol, triglycerides, serum creatinine, fasting glucose, angina functional class, and previous myocardial infarction. Nonpredictive variables from the preoperative catheterization were aortic mean pressure, left ventricular end-diastolic pressure, ejection fraction, and the presence of collaterals originating from the grafted vessel. Intraoperative determinations of little value in predicting graft occlusion were the presence of moderate or severe arterial disease at the anastomotic site, the surgeon (there were two attending surgeons, R. C. and J. C.), and the type of myocardial preservation used. Postoperatively, cigarette smoking, blood pressure, postoperative ejection fraction, and outpatient compliance with therapy were not predictive of occlusion. Graft occlu-sion was strongly associated with left ventricular enddiastolic pressure of 12 mm Hg or greater at the postoperative catheterization (22% vs 9%; p < .01). This was most likely an effect of graft occlusion rather than a cause, because an elevated preoperative left ventricular end-diastolic pressure had no predictive value. Consequently, postoperative left ventricular end-diastolic pressure was not included as one of the covariates in the logistic regression analysis. Similarly, bleeding time, significantly altered by therapy, was not included as a predictive covariate. Finally, anastomotic luminal diameter measured from the preoperative arteriogram correlated highly with the operative estimate, and therefore was not included.
The six variables significantly associated with graft occlusion in either the placebo or the drug-treated subsets are listed in table 2. For purposes of illustration, these graft risk factors were dichotomized into highrisk and low-risk categories. For example, if operative luminal diameter at the site of graft anastomosis was greater than 1.5 mm, graft occlusion in the ASA and ASA + DP groups was 8% vs 29% (p < .001) for smaller vessels in the same therapy group.
Effectiveness of therapy: overall graft patency. Fiftynine percent of 44 patients taking placebo had all grafts patent, compared with 67% of 45 taking ASA + DP and 74% of 38 taking ASA.
Results of the logistic regression analysis testing the effects of therapy are given in table 3. The statistical model estimated the probability of graft occlusion in each of the treatment groups at comparable levels of the other covariates. The odds ratio, defined above, provides an estimate of the risk of occlusion in the treated group relative to that in the placebo group with all other significant covariates being equal. The data in table 3 indicate statistically significant overall therapeutic benefit for the group receiving ASA (odds ratio = 0.47, p = .04) and for the group receiving ASA + DP (odds ratio = 0.50, p = .04). A test comparing the two treatment groups indicated no significant difference (Z = 0.18, p = .86). This beneficial effect of therapy is demonstrated in the simple proportion of grafts occluded, which was 21% in the placebo group, 14% in the ASA + DP group, and 12% in the ASA group. The odds ratios are not exactly equal to the ratios of simple proportions because of small differences in distributions of the six covariates biasing in favor of placebo and against ASA + DP (see table 2 ). Adjustments were made for this in the logistic model.
Although the traditional coronary risk factors (age, cigarette smoking, diastolic blood pressure, cholesterol, and fasting glucose) were not found to be signifi- APIT subgroup includes patients on ASA and those on ASA + DP. BValues in parentheses are the numbers of grafts at risk of occlusion in each subgroup.
cantly related to graft occlusion, they were included with the above six graft-specific covariates in a larger logistic regression analysis that tested for effects of therapy. The results were virtually identical with those of the above analysis (relative risk for ASA = 0.41, p -.03; and for ASA + DP = 0.44, p = .02). Initiation of therapy. Data relating graft patency to the time of initiation of platelet-inhibiting therapy appear in figure 1. Forty-nine patients began therapy on the second postoperative day (.60 hr after surgery). Among these, 13 of 56 (23%) grafts in patients in the placebo group, three of 39 (8%, p < .05) in those in aspirin, 650 mg bid, begun on the first postoperative day.39 W = ASA or ASA + DP started between the second and the fifth postoperative day (data from this report). P ASA + DP started on the third or fourth postoperative day.9 MG Aspirin, 325 mg bid, started on the third or fourth postoperative day.38 R = Aspirin or aspirin plus dipyridamole started on third, fourth, or fifth postoperative day.42 X2 statistical comparison of treated grafts vs same-day controls: *p < .05. # <.02; **p < .001. the ASA group, and seven of 59 (12%, NS) in those in the ASA + DP group were occluded. Seventy-eight patients began therapy on the third postoperative day or later. Among these, 18 of 91 (20%) grafts in patients in the placebo group, 1 1 of 75 (15%, NS) in those in the ASA group, and 13 of 79 (16%, NS) in those in the ASA + DP group were occluded. All 34 grafts were patent in 11 patients starting ASA or ASA + DP less than 48 hr after surgery; 19 of 26 grafts were patent in seven comparable patients on placebo (p < .001).
Effect of therapy: occlusion in certain important graft subsets. Is the observed beneficial effect of therapy uniform or is it selective for certain subgroups? To address this question, separate logistic analyses were conducted in each of three particularly important graft subgroups to estimate the effects in the therapy groups while adjusting for the effects of the six covariates previously identified. In the following discussion, graft flow is designated as "good" if it was greater than 40 ml/min and "low" if it was less. Arteries are called "small" if luminal diameter at the point of anastomosis was 1.5 mm or less, and "larger" if it was greater than that. Reactive hyperemia is called present if it was at least 10% above baseline flow and absent if it was less. Figure 2 demonstrates that 74% of the 399 grafts studied were to larger arteries; in this subset a 69% reduction in the odds of occlusion was obtained with platelet-inhibiting therapy. There was no difference in Effect of therapy on overall graft occlusion and in certain subgroups: results of the logistic regression analysis. The relative risk of occlusion compared with the unit risk with placebo was significantly reduced by treatment with ASA alone or with ASA + DP. Certain large subsets of the graft population obtained an even greater relative benefit from therapy, as shown. Conversely, treatment had no significant effect on the relative risk of occlusion for grafts to arteries with luminal diameters of 1.5 mm or less (relative risk: ASA = 0.77; ASA + DP = 0.90). grafts with flow of 40 ml/min or less (ASA = 0.89; ASA + DP = 1.09), and those with reactive hyperemia 10% or more above baseline flow (ASA = 0.89; ASA + DP = 1.35).
the odds ratio with ASA (0.32; p < .05) or ASA + DP (0.31; p < .05). Sixty-nine percent of grafts had good flow; in this subset a mean 65% reduction in the odds of occlusion was obtained with either ASA (0.30; p < .01) or ASA + DP (0.39; p < .05). Forty-eight percent of grafts lacked reactive hyperemia. 30 In this subset a mean 74% reduction in the odds of occlusion was obtained with either ASA (0.27; p < .01) or ASA + DP (0.25; p < .01). Clinical benefit. Does graft patency correlate with clinical benefit? To address this question, we measured changes in certain objectively defined indexes of the surgical benefit and correlated them with graft occlusion. Table 4 summarizes this analysis. Sixty-six patients had angina during their preoperative treadmill test; an additional 19 had spontaneous resting angina with ST-T changes and did not undergo exercise testing preoperatively. Of these, 19 (22%) had some degree of angina during the postoperative exercise stress. Table 4 shows that only 13% of these patients with all grafts patent had persistent pain, compared with 25% of patients with one occluded graft and 54% of those with two or more occluded (p < .02). Similar observations were made for two other signs of myocardial ischemia: exercise-induced ST segment abnormalities and left ventricular compliance abnormalities. Thus, impressive clinical, electrocardiographic, and hemodynamic improvements resulted from coronary bypass surgery and, in all cases, lack of improvement in these three indexes of myocardial ischemia was significantly related to the number of occluded grafts. 
Discussion
Although ASA and DP appear to be appropriate agents to test the hypothesis that platelet-inhibiting therapy can improve aortocoronary graft paten-cy21, 24, [31] [32] [33] [34] [35] [36] [37] contradictory conclusions have been reached in published studies9 38-41 and preliminary re-ports42 of the use of these drugs after bypass surgery. While a number of considerations may help to account for these discrepancies, the time of initiation of drug therapy may be the most important. Chesebro and Fuster and their colleagues40 4 1 have emphasized the importance of starting therapy early; they report a convincing benefit from DP begun 48 hr before surgery and continued in combination with ASA soon after operation. Rate of graft occlusion at 1 year in their placebo-treated patients was 25%; in ASA + DP patients, it was 11%. The relationships among therapy, the time of its initiation, and graft occlusion are illustrated in figure 1 , in which data from this trial are compared with those from five other trials.9 38 39, 41-42 Substantial benefits are associated with initiation of therapy before surgery or on the first or second postoperative day. Unfortunately, in many of the previously reported studies therapy was begun on the third to fifth postoperative daytoo late to realize the potential benefits.
It may not be necessary to pharmacologically inhibit platelet function in the immediate perioperative period, because platelet counts43 and adhesiveness' are acutely suppressed by the trauma of cardiopulmonary bypass. Indeed, among 91 of our 127 patients for whom adequate data were available, the mean platelet count was 229,000 ± 75,000(SD) before surgery, 105,000 immediately after surgery, 122,000 on the first postoperative day, and 101,000 in 30 of these patients for whom samples were considered clinically indicated on the second postoperative day. Dewanjee et al. 45 found no difference between treated and untreated dogs with respect to platelet adhesion to autologous saphenous vein grafts on the first postoperative day, although platelet-inhibiting drugs suppressed adhesion on postoperative days 3 to 30.
The data in table 2 and figure 2 provide insight into the mechanisms of graft occlusion. Arterial size appears to be an independent determinant of the risk of occlusion, presumably for technical reasons. While good operative flow was predictive of graft patency, our data suggest that reactive hyperemia correlates with patency even more strongly. The absence of reactive hyperemia appears to indicate that the distal coronary bed is graft independent in patients in the resting state. Eighty-four percent of grafts with 10% or less reactive hyperemia were associated with either moderate (<70%) proximal stenosis or with a developed collateral supply to the distal bed. Thus, grafts that are necessary for perfusion at rest appear to have a built-in safeguard against occlusion, but grafts that compete with the native vessel or with well-developed collaterals in the resting postoperative state lack this safeguard. In this latter setting, platelet-inhibiting therapy appears to alter the delicate dynamic balance to preserve patency in 74% of such grafts that would otherwise progress to occlusion. Therefore, as surgeons begin to bypass an increasing number of moderately diseased arteries in multigraft procedures, use of platelet-inhibiting therapy will help to avoid undesirably high occlusion rates.
Clinical implications. Overall graft patency, particularly of those grafts without reactive hyperemia. those with good flow, and those to larger arteries, was clearly improved by platelet-inhibiting therapy in this study. All but one of our patients had at least one graft with at least one of these characteristics. Therefore, if intraoperative measurements have identified such a graft, or in the absence of these measurements, we recommend that platelet-inhibiting therapy be initiated, unless contraindicated, no later than 48 hr after operation.
What is the "best" platelet-inhibiting regimen? The data of this study support the position that, postoperatively, ASA is as effective as ASA + DP. Additional data are not available; there has been no other graft patency trial comparing ASA with combined therapy and placebo in which therapy was started sufficiently early to expect a benefit. In particular, no clinical trial to date has examined the comparative efficacy of preoperative vs early postoperative initiation of therapy. The data in figure 1 support the position that ASA or ASA + DP, started on the first or second postoperative day, is as effective as a regimen requiring preoperative dipyridamole. Despite its popularity and experimentally predicted superiority, the combined drug regimen has not been clinically proven to be more effective than ASA alone for preventing thrombosis in the arterial circulation.46 '47 In conclusion, this study adds to information emerging from other such trials. This is the second largest of the six controlled studies to date. It uses appropriate statistical methods to adjust for imbalances in the nondrug determinants of graft occlusion; it demonstrates a substantial overall therapeutic benefit, and an even greater benefit to several clinically important graft subsets; it supports and extends current understanding of the need for early initiation of therapy; and its results permit a plausible mechanistic interpretation of the importance of graft reactive hyperemia. We believe that available data support the position that therapy with 325 mg of oral ASA three times a day, begun within 48 hr of operation, provides a substantial benefit with respect to graft patency, particularly in patients with grafts with good flow supplying larger arteries. Although we did not find that additional DP further improved graft patency, this study does not directly exclude the possibility of added benefit from preoperative DP continued postoperatively with ASA.4041 Furthermore, use of DP may be considered because of the small advantage of combined therapy over ASA alone in preventing perianastomotic arterial stenosis at the graft site,48 or because of the possible,24 but currently unproved,49 advantage of use of combined therapy in retarding the progression of native coronary or graft atherosclerosis. The minimum daily dose50 and minimum required period of treatment are unknown, and further studies are necessary for their definition.
